Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study, a 74-year-old patient with frontal fibrosing alopecia displayed unique trichoscopic and histopathological features, and treatments like 5-alpha reductase inhibitors and oral minoxidil effectively halted disease progression, highlighting the importance of comprehensive facial analysis for prognosis.

This study observed that using a 1064 nm Nd: YAG laser may stabilize hair loss and promote new growth in some females with frontal fibrosing alopecia, though individual results varied.

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

This study suggests a potential causal link between frontal fibrosing alopecia and vitiligo, as observed in two cases where the conditions co-occurred on preexisting vitiligo of the forehead.

This study observed that among a Moroccan population with frontal fibrosing alopecia, common comorbidities included lichen planus pigmentosus (36.8%), rosacea (28.9%), thyroid disorders (23.7%), and dyslipidemia (21.1%), highlighting potential relationships mediated by shared inflammatory or metabolic pathways.

Isolated long hairs at the original hairline can help diagnose Frontal Fibrosing Alopecia.

The authors concluded that Hispanic/Latino ethnicity, facial papules, and premenopausal status in patients with frontal fibrosing alopecia may indicate a susceptibility to more severe disease, potentially necessitating early treatment.

This study found that serum FABP4 levels were significantly higher in alopecia areata patients compared to healthy controls and may correlate with disease severity.

This study found that postmenopausal women in Argentina with frontal fibrosing alopecia had a higher average age of diagnosis than previously reported, with similar clinical features to international cases.

This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.

This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.

This article discusses the connection between product use, contact dermatitis, and frontal fibrosing alopecia and reports no new findings; the authors emphasize the need for more research to improve patient outcomes.

In this study, the researchers identified a temperature-sensitive mutant in Arabidopsis thaliana, showing disrupted root hair formation and altered responses to plant hormone treatments at elevated temperatures.

This study observed that combining high-potency steroids with pimecrolimus might effectively stabilize hairline recession in frontal fibrosing alopecia patients.

This study proposes that seasonal alopecia and reproductive changes in six female fossas at the San Diego Zoo may be linked to hormonal changes associated with reproductive activity.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This study found that polycystic ovary syndrome was the most common cause of hirsutism among premenopausal women in Algeria.

This study found that the free androgen index (FAI) is a superior marker of hyperandrogenism in men with premature androgenetic alopecia compared to DHEAS and testosterone levels.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

This case report describes a 66-year-old man with frontal fibrosing alopecia, a rare lichen planopilaris variant, presenting with scarring alopecia at the hairline and extensive body hair loss.

This study identified four circulating microRNAs as highly predictive of frontal fibrosing alopecia status, suggesting potential roles in diagnostics and disease understanding.

This review highlights increased cases of alopecia frontal fibrosante among Black women, emphasizing the need for ethnically diverse research and culturally sensitive management practices, but reports no new clinical findings.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

This case study diagnosed a 60-year-old woman with frontal fibrosing alopecia after histopathological analysis showed characteristic scarring patterns in the hairline area.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

This study describes a newly observed "inflammatory vellus involvement" pattern in early frontal fibrosing alopecia, which may lead to misdiagnosis due to the absence of typical histological features.

This dissertation demonstrates that FERONIA regulates essential plant functions such as RAC/ROP signaling, pollen tube reception, cell wall integrity, and sugar signaling as a cell surface receptor kinase.

Hair loss in male frontal fibrosing alopecia may spare areas covered by a wristwatch.

This study demonstrated that Forsythiaside A improved survival and reduced neurological deficits in rats with cerebral ischemic injury, potentially through activating Nrf2 and reducing ER stress pathways.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.